These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 21333634)

  • 1. The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome.
    Hampson DR; Adusei DC; Pacey LK
    Biochem Pharmacol; 2011 May; 81(9):1078-86. PubMed ID: 21333634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragile X syndrome and autism at the intersection of genetic and neural networks.
    Belmonte MK; Bourgeron T
    Nat Neurosci; 2006 Oct; 9(10):1221-5. PubMed ID: 17001341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in behavioral genetics: mouse models of autism.
    Moy SS; Nadler JJ
    Mol Psychiatry; 2008 Jan; 13(1):4-26. PubMed ID: 17848915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans.
    Won J; Jin Y; Choi J; Park S; Lee TH; Lee SR; Chang KT; Hong Y
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28632163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autism and fragile X syndrome.
    Yu TW; Berry-Kravis E
    Semin Neurol; 2014 Jul; 34(3):258-65. PubMed ID: 25192504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered expression of Autism-associated genes in the brain of Fragile X mouse model.
    Zhang A; Shen CH; Ma SY; Ke Y; El Idrissi A
    Biochem Biophys Res Commun; 2009 Feb; 379(4):920-3. PubMed ID: 19138667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.
    Berry-Kravis E
    Pediatr Neurol; 2014 Apr; 50(4):297-302. PubMed ID: 24518745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Autism in fragile X syndrome].
    García-Nonell C; Rigau-Ratera E; Artigas-Pallarés J
    Rev Neurol; 2006 Feb; 42 Suppl 2():S95-8. PubMed ID: 16555225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early acceleration of head circumference in children with fragile x syndrome and autism.
    Chiu S; Wegelin JA; Blank J; Jenkins M; Day J; Hessl D; Tassone F; Hagerman R
    J Dev Behav Pediatr; 2007 Feb; 28(1):31-5. PubMed ID: 17353729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioural and cognitive phenotypes in idiopathic autism versus autism associated with fragile X syndrome.
    Dissanayake C; Bui Q; Bulhak-Paterson D; Huggins R; Loesch DZ
    J Child Psychol Psychiatry; 2009 Mar; 50(3):290-9. PubMed ID: 19175809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prader-Willi phenotype of fragile X syndrome.
    Nowicki ST; Tassone F; Ono MY; Ferranti J; Croquette MF; Goodlin-Jones B; Hagerman RJ
    J Dev Behav Pediatr; 2007 Apr; 28(2):133-8. PubMed ID: 17435464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in fragile X: a model for autism and neurodegeneration.
    Hagerman RJ; Ono MY; Hagerman PJ
    Curr Opin Psychiatry; 2005 Sep; 18(5):490-6. PubMed ID: 16639106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.
    Lozano R; Martinez-Cerdeno V; Hagerman RJ
    Curr Pharm Des; 2015; 21(34):4972-4979. PubMed ID: 26365141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief review of current research in FXS: implications for treatment with psychotropic medication.
    Valdovinos MG
    Res Dev Disabil; 2007; 28(6):539-45. PubMed ID: 17034990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy for Fragile X Syndrome: Progress to Date.
    Davenport MH; Schaefer TL; Friedmann KJ; Fitzpatrick SE; Erickson CA
    Drugs; 2016 Mar; 76(4):431-45. PubMed ID: 26858239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Social behavior phenotypes in fragile X syndrome, autism, and the Fmr1 knockout mouse: theoretical comment on McNaughton et al. (2008).
    Brodkin ES
    Behav Neurosci; 2008 Apr; 122(2):483-9. PubMed ID: 18410188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overlapping Molecular Pathways Leading to Autism Spectrum Disorders, Fragile X Syndrome, and Targeted Treatments.
    Salcedo-Arellano MJ; Cabal-Herrera AM; Punatar RH; Clark CJ; Romney CA; Hagerman RJ
    Neurotherapeutics; 2021 Jan; 18(1):265-283. PubMed ID: 33215285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathways to drug development for autism spectrum disorders.
    Hampson DR; Gholizadeh S; Pacey LK
    Clin Pharmacol Ther; 2012 Feb; 91(2):189-200. PubMed ID: 22205199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS).
    D'Hulst C; Heulens I; Brouwer JR; Willemsen R; De Geest N; Reeve SP; De Deyn PP; Hassan BA; Kooy RF
    Brain Res; 2009 Feb; 1253():176-83. PubMed ID: 19070606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic factors and epigenetic factors for autism: endoplasmic reticulum stress and impaired synaptic function.
    Momoi T; Fujita E; Senoo H; Momoi M
    Cell Biol Int; 2009 Dec; 34(1):13-9. PubMed ID: 20001973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.